Featured Research

from universities, journals, and other organizations

"Trojan Horse" Technology Destroys Blood Supply To Cancer Tumors In Mice

Date:
June 11, 2002
Source:
University Of Texas Southwestern Medical Center At Dallas
Summary:
Researchers at The University of Texas M. D. Anderson Cancer Center in Houston and The University of Texas Southwestern Medical Center at Dallas have demonstrated in mice that a new drug formed by linking a vascular endothelial growth factor to a toxin will target and destroy the blood vessels supplying a malignant tumor.

Researchers at The University of Texas M. D. Anderson Cancer Center in Houston and The University of Texas Southwestern Medical Center at Dallas have demonstrated in mice that a new drug formed by linking a vascular endothelial growth factor to a toxin will target and destroy the blood vessels supplying a malignant tumor.

Related Articles


Dr. Michael Rosenblum, Professor of Medicine at M. D. Anderson, said tests of VEGF121/rGelonin (VEGF/rGel) in mice demonstrated it could selectively destroy blood vessels supplying human solid tumors without harming the vasculature of normal tissue.

"This is like a 'Trojan horse' approach to kill the blood vessels that supply solid tumors. We're using the vascular endothelial growth factor (VEGF) as a carrier to deliver a toxic agent selectively to the tumor's blood supply – in effect, starving the tumor," said Dr. Rosenblum, senior author of the study.

The research, which appears in the June 11 Proceedings of the National Academy of Sciences, was the result of an ongoing collaboration between UT Southwestern and M. D. Anderson. VEGF/rGel was designed jointly and developed at M. D. Anderson and UT Southwestern.

For the study, mice were injected with human melanoma and human prostate cancer cells. The research showed that tumor growth in the mice that received VEGF/rGel was reduced to 16 percent of that of the untreated mice, said Dr. Philip Thorpe, Professor of Pharmacology, who directed tests of VEGF/rGel at UT Southwestern with Dr. Sophia Ran, Assistant Professor of Pharmacology. Both are affiliated with the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.

"The anti-tumor effects of the VEGF/rGel fusion construct against both melanoma and human prostate cancer in mouse models was impressive in magnitude and prolonged," Dr. Thorpe said. "These studies suggest that VEGF/rGel has potential as an anti-tumor agent for treating cancer patients."

A clinical trial to test the new technique in patients is expected to begin within the year at M. D. Anderson, Dr. Rosenblum said.

"The significance of this fusion toxin is that it's not specific to one kind of tumor – it has impressive anti-tumor effects in various kinds of tumors – including melanoma and prostate cancers," Dr. Rosenblum said. "We need additional research to determine if it is equally effective in other cancers."

In the mouse study, destruction of the tumor blood vessels was observed as early as 48 hours after administration of the VEGF/rGel. There was no visible damage in any normal organs, including the kidneys, of the treated mice, Dr. Rosenblum said.

VEGF is one of the predominant factors responsible for angiogenesis – the ability of a tumor to create new blood vessels to maintain growth and metastasize.

"The receptors for VEGF are overexpressed on the endothelium of tumor vasculature but are almost undetectable in the adjacent normal tissue, so they make excellent targets for the development of therapeutic agents that inhibit tumor growth and metastatic spread by inhibiting the new blood vessel formation," Dr. Rosenblum said.

The researchers chose the genetically engineered toxin gelonin to link to the VEGF "carrier" because it does not appear to be antigenic in human clinical trials conducted thus far at M. D. Anderson, and it does not cause damage to normal blood vessels as do other toxins that have been explored for use in anti-tumor therapies, Dr. Rosenblum said.

Genetically engineered gelonin was developed in a research program at M. D. Anderson, and related intellectual property rights are owned by Research Development Foundation (RDF). RDF is in the process of licensing the gelonin technology for use with various cell-targeting proteins such as growth factors and antibodies.

Therapies that attack tumor blood vessels have recently been a hot area in cancer research because they appear to bypass the major problem with chemotherapy – the tumor cells' ability to mutate and develop resistance to the drugs.

Other researchers from M. D. Anderson who contributed to the work were Liesbeth M. Veenendaal, Lawrence Cheung, Nora Navone and Hangqing Jin. The Med. Klinik und Poliklinik der Universitδt Ulm in Germany also contributed to the research.

The work was supported in part by the University of Utrecht and the Dutch Cancer Foundation, Koningen Wilhelmina Funds, the National Institutes of Health and Arcus Therapeutics.


Story Source:

The above story is based on materials provided by University Of Texas Southwestern Medical Center At Dallas. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas Southwestern Medical Center At Dallas. ""Trojan Horse" Technology Destroys Blood Supply To Cancer Tumors In Mice." ScienceDaily. ScienceDaily, 11 June 2002. <www.sciencedaily.com/releases/2002/06/020611071243.htm>.
University Of Texas Southwestern Medical Center At Dallas. (2002, June 11). "Trojan Horse" Technology Destroys Blood Supply To Cancer Tumors In Mice. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2002/06/020611071243.htm
University Of Texas Southwestern Medical Center At Dallas. ""Trojan Horse" Technology Destroys Blood Supply To Cancer Tumors In Mice." ScienceDaily. www.sciencedaily.com/releases/2002/06/020611071243.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) — As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
Dads-To-Be Also Experience Hormone Changes During Pregnancy

Dads-To-Be Also Experience Hormone Changes During Pregnancy

Newsy (Dec. 18, 2014) — A study from University of Michigan researchers found that expectant fathers see a decrease in testosterone as the baby's birth draws near. Video provided by Newsy
Powered by NewsLook.com
Prenatal Exposure To Pollution Might Increase Autism Risk

Prenatal Exposure To Pollution Might Increase Autism Risk

Newsy (Dec. 18, 2014) — Harvard researchers found children whose mothers were exposed to high pollution levels in the third trimester were twice as likely to develop autism. Video provided by Newsy
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) — Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins